国家卫生系统特征、乳腺癌诊断分期与乳腺癌死亡率:一项基于人群的分析
该研究基于GLOBOCAN 2020和WHO癌症国家概况数据,分析148个国家卫生系统特征与乳腺癌年龄标化死亡率的关系,并在141个国家调整回归中发现UHC指数较高和公立癌症中心数量较多与较低死亡率显著相关;35个有分期数据的国家中,20个持续死亡率年降≥2%的国家均至少60%患者初诊为I/II期。
要点
- UHC指数每增加1单位,乳腺癌年龄标化死亡率下降0·12单位。
- 每万名癌症患者公立癌症中心每增加1个,年龄标化死亡率下降0·23单位。
- 持续死亡率年降≥2%的国家均至少60%初诊为I/II期。
核心结论
- 乳腺癌低死亡率国家特征为基本卫生服务覆盖水平较高和公立癌症中心数量较多。
- 实现持续死亡率下降的国家多数乳腺癌初诊为早期,支持临床早期诊断规划的价值。
研究设计与样本
- 基于人群研究,从GLOBOCAN 2020获取≤69岁女性年龄标化死亡率估计,与WHO癌症国家概况2020卫生系统数据关联。
- 148个国家有完整卫生系统数据,141个国家纳入调整多因素回归分析。
- TNM分期数据来自国家或地方癌症登记,并补充2010至2020年PubMed文献复习;死亡率趋势用WHO癌症死亡率数据库评估。
主要发现
- 高收入国家较低收入国家显著更高:卫生支出(p=0·0002)、UHC指数(p<0·0001)、早期发现专项经费(p=0·0020)、乳腺癌早期发现指南(p<0·0001)、转诊系统(p=0·0030)、国家癌症计划(p=0·014)、宫颈癌早期发现规划(p=0·0010)、每万名癌症患者公立癌症中心数(p<0·0001)和私立癌症中心数(p=0·027)、病理服务(p<0·0001)。
- 141个国家调整多因素回归中,较高UHC指数(β=-0·12,95%CI -0·16至-0·08)和更多公立癌症中心(β=-0·23,95%CI -0·36至-0·10)与较低年龄标化死亡率显著相关。
- 35个有乳腺癌TNM分期数据的国家中,20个自1990年以来至少连续3年年龄标化死亡率年均持续下降≥2%,这20国均至少60%浸润性乳腺癌初诊为I或II期。
- 部分国家在多数女性未获得基于人群的乳腺X线筛查情况下也实现了上述死亡率下降。
关键数值与推荐
- UHC指数每增加1单位与年龄标化死亡率下降0·12单位相关(β=-0·12,95%CI -0·16至-0·08)。
- 每万名癌症患者公立癌症中心每增加1个与年龄标化死亡率下降0·23单位相关(β=-0·23,95%CI -0·36至-0·10)。
- 持续死亡率年降≥2%至少连续3年的国家均至少60%浸润性乳腺癌初诊为I或II期。
临床怎么用
- 肿瘤内科医生可关注本国UHC覆盖和公立癌症中心可及性对乳腺癌分期和死亡率的潜在影响。
- 推动临床早期诊断以促进I/II期初诊,即使人群乳腺X线筛查覆盖有限也可能改善结局。
局限性
- 研究为基于国家层面数据的关联分析,不能证明因果关系。
- TNM分期数据仅35个国家可得,且部分来自地方登记和文献复习,存在异质性。
- 部分国家在多数女性未接受人群乳腺X线筛查下实现死亡率下降,提示其他因素可能参与。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In some countries, breast cancer age-standardised mortality rates have decreased by 2-4% per year since the 1990s, but others have yet to achieve this outcome. In this study, we aimed to characterise the associations between national health system characteristics and breast cancer age-standardised mortality rate, and the degree of breast cancer downstaging correlating with national age-standardised mortality rate reductions. METHODS: In this population-based study, national age-standardised mortality rate estimates for women aged 69 years or younger obtained from GLOBOCAN 2020 were correlated with a broad panel of standardised national health system data as reported in the WHO Cancer Country Profiles 2020. These health system characteristics include health expenditure, the Universal Health Coverage Service Coverage Index (UHC Index), dedicated funding for early detection programmes, breast cancer early detection guidelines, referral systems, cancer plans, number of dedicated public and private cancer centres per 10 000 patients with cancer, and pathology services. We tested for differences between continuous variables using the non-parametric Kruskal-Wallis test, and for categorical variables using the Pearson χ2 test. Simple and multiple linear regression analyses were fitted to identify associations between health system characteristics and age-standardised breast cancer mortality rates. Data on TNM stage at diagnosis were obtained from national or subnational cancer registries, supplemented by a literature review of PubMed from 2010 to 2020. Mortality trends from 1950 to 2016 were assessed using the WHO Cancer Mortality Database. The threshold for significance was set at a p value of 0·05 or less. FINDINGS: 148 countries had complete health system data. The following variables were significantly higher in high-income countries than in low-income countries in unadjusted analyses: health expenditure (p=0·0002), UHC Index (p<0·0001), dedicated funding for early detection programmes (p=0·0020), breast cancer early detection guidelines (p<0·0001), breast cancer referral systems (p=0·0030), national cancer plans (p=0·014), cervical cancer early detection programmes (p=0·0010), number of dedicated public (p<0·0001) and private (p=0·027) cancer centres per 10 000 patients with cancer, and pathology services (p<0·0001). In adjusted multivariable regression analyses in 141 countries, two health system characteristics were significantly associated with lower age-standardised mortality rates: higher UHC Index levels (β=-0·12, 95% CI -0·16 to -0·08) and increasing numbers of public cancer centres (β=-0·23, -0·36 to -0·10). These findings indicate that each unit increase in the UHC Index was associated with a 0·12-unit decline in age-standardised mortality rates, and each additional public cancer centre per 10 000 patients with cancer was associated with a 0·23-unit decline in age-standardised mortality rate. Among 35 countries with available breast cancer TNM staging data, all 20 that achieved sustained mean reductions in age-standardised mortality rate of 2% or more per year for at least 3 consecutive years since 1990 had at least 60% of patients with invasive breast cancer presenting as stage I or II disease. Some countries achieved this reduction without most women having access to population-based mammographic screening. INTERPRETATION: Countries with low breast cancer mortality rates are characterised by increased levels of coverage of essential health services and higher numbers of public cancer centres. Among countries achieving sustained mortality reductions, the majority of breast cancers are diagnosed at an early stage, reinforcing the value of clinical early diagnosis programmes for improving breast cancer outcomes. FUNDING: None.
引用
- Duggan C, Trapani D, Ilbawi AM, et al. National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. Lancet Oncol. 2021. PMID: 34653370. doi:10.1016/S1470-2045(21)00462-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。